<?xml version="1.0" encoding="UTF-8"?>
<p>The pharmacokinetic‐evaluable population comprised all phase 1 patients with sufficient dosing and ixazomib concentration–time data to permit calculation of ixazomib plasma pharmacokinetic parameters, which were calculated on days 1 and 11 of cycle 1 using non‐compartmental analysis methods (Phoenix WinNonlin version 6·2, Pharsight, a Certara Company, Princeton, NJ, USA).</p>
